Abstract: A device for attaching a primary implant as a fixation point for a vascular prosthesis on a vessel wall of a blood vessel, the device at least including a carrier element, which is designed to drive a plurality of penetration elements, for penetrating the vessel wall, radially outwards in relation to a longitudinal axis of the carrier element. In the device, a limiting element is formed on the carrier element as a radial stop for the penetration elements.

Abstract: Method for producing a light-curable resin composition capable of producing a magnetic resonance imaging-signal, in particular for the lithography-based additive production of magnetic resonance imaging phantoms, the method comprising at least the following steps: providing particles at least partially filled with a magnetic resonance imaging-signal producing liquid, and mixing the at least partially filled particles with a light-curable resin.

Abstract: The invention relates to a device for connecting a cannula to a container under reduced pressure, in particular a blood culture flask, including an inflow opening for connecting to the cannula or to a connection tube connected to the cannula, an outflow opening for connecting to a hollow pin for piercing a closure of the container, and a tight fluidic connection of the inflow opening to the outflow opening. According to the invention, a reservoir which is separated from the fluidic connection and contains a specified gas quantity is connected to the fluidic connection with the interposition of a valve which is preferably open towards the fluidic connection.

Abstract: The present invention relates to a method for the in vitro detection of a latent tuberculosis infection (LTBI) in a subject, wherein said method comprises determining at least one nucleotide sequence and/or at least one polypeptide of Mycobacterium tuberculosis (Mtb) in a blood cell population of said subject, and wherein the presence of said at least one nucleotide sequence and/or said at least one polypeptide is indicative for said latent tuberculosis infection. In particular, the blood cell population is enriched for hematopoietic stem cells. The invention also relates to a pharmaceutical composition for use in the treatment of the LTBI in the subject, wherein it is determined if the nucleotide sequence and/or the polypeptide of Mtb is/are present in the blood cell population. Further, the invention relates to kits for carrying out the methods of the invention. The invention also relates to the use of the kits.

Abstract: The present invention relates to an antibody specifically binding the carboxymethylated catalytic subunit of protein phosphatase 2A (PP2Ac). Also provided are diagnostic uses of said antibody and screening methods employing the inventive antibody.

Abstract: The present invention relates to novel monomaleimide-functionalized platinum compounds of formula (I), including in particular novel monomaleimide-functionalized oxaliplatin and carboplatin derivatives, as well as their use as medicaments, particularly for the treatment or prevention of cancer.

Abstract: The present invention provides a pharmaceutical composition for use in prevention or treatment of a human rhinovirus (HRV) infection. The composition comprises an aldohexose, wherein the hydroxyl group at carbon 2 of the aldohexose is replaced by any one of H, F, Cl, Br, I, SH, Me, OMe and SMe, such as a 2-deoxy-glucose. Furthermore, a dispenser for intranasal administration, such as a nasal spray or nose drop applicator containing said pharmaceutical composition is provided. In addition, an inhalation device, such as a metered-dose inhaler, a dry-powder inhaler or a nebuliser, comprising said composition is provided.

Abstract: The invention relates to an in vitro method of determining a subjects risk of liver dysfunction, specifically after partial liver resection, said method comprising the steps of providing a sample from said subject, determining in said sample the expression level of at least one miRNA, selected from the group consisting of miR-151a, miR-192 and miR-122, and comparing these expression level(s) with at least one reference expression level, or identifying the ratios of the expression levels of miR-15 la to miR-192 and/or of miR-122 to miR-151a and comparing said expression level ratios with reference expression level ratios, and classifying the sample from the outcome of the comparison into one of at least two classes, wherein each class is one of the at least two categories “high-risk” and “low-risk”.

Abstract: A device for feeding and setting an implant into a blood vessel includes a hollow cylindrical portion formed of an expandable wire mesh netting with a first end and a second end, with a sleeve for receiving the implant in a radially compressed state. The sleeve is arrangeable along a guide wire. The sleeve for receiving the implant in the radially compressed state is formed by an inner sleeve, around which at least one outer sleeve with a distal end and a proximal end is arranged. The implant is arranged in the inner sleeve in such a way that the second end of the hollow cylindrical portion is arranged on the end facing the proximal end of the outer sleeve, so that during setting of the implant, the inner sleeve surrounding the implant can be moved into the outer sleeve in the distal direction so that the implant expands, beginning from the second end.

Abstract: The present invention relates to a method for predicting the neurological outcome of a patient after cardiac arrest, the method comprising the step(s) of: (I) a) determining the level of alpha-enolase in a biological sample obtained from a patient after cardiac arrest; and b) comparing the level of alpha-enolase obtained in (a) with the median or mean level of alpha-enolase in biological samples from patients with positive neurological outcome after cardiac arrest, wherein said patient is diagnosed as having a negative neurological outcome if the alpha-enolase level is increased by at least 100% over the median or mean level of alpha-enolase, and/or a positive neurological outcome if the alpha-enolase level is below 150% as compared to the median or mean level of alpha-enolase; or (II) determining the level of alpha-enolase in a biological sample obtained from a patient after cardiac arrest, wherein said patient is diagnosed as having a negative neurological outcome if the alpha-enolase level is above 50 ?g/L

Abstract: Methods and apparatus for designing a skull prosthesis are disclosed. In one arrangement, imaging data from a medical imaging process is received. The imaging data represents the shape of at least a portion of a skull. The imaging data is used to display on a display device a first virtual representation of at least a portion of the skull. User input defining a cutting line in the first virtual representation is received. A surgical operation of cutting through the skull along at least a portion of the defined cutting line to at least partially disconnect a target portion of the skull from the rest of skull is simulated. Output data is provided based on the simulation. The output data represents a simulated shape of at least a portion of the skull with the target portion at least partially disconnected from the rest of the skull, thereby defining the shape of an implantation site for a skull prosthesis to be manufactured.

Abstract: The present invention relates to a mutant thymidine kinase, specifically a mutant human thymidine kinase 1 (Tkl1). The activity of the mutant thymidine kinase is increased compared to the activity of wildtype thymidine kinase. Provided herein are uses of the mutant thymidine kinase in therapy, such as in cancer therapy. Also methods of treating cancer comprising administering the mutant thymidine kinase are disclosed herein. The present invention relates, inter alia, to a nucleic acid for use hi treating cancer, wherein said nucleic acid comprises a nucleotide sequence, wherein said nucleotide sequence encodes a mutant thymidine kinase.

Abstract: The present invention relates to a method and a device for a nucleic acid based diagnostic approach including the determination of a deviant condition of a sample, wherein the deviant condition is preferably a health condition and/or a pathogenic condition.

Abstract: The present invention relates to novel monomaleimide-functionalized platinum compounds of formula (I), including in particular novel monomaleimide-functionalized oxaliplatin and carboplatin derivatives, as well as their use as medicaments, particularly for the treatment or prevention of cancer.

Abstract: The present invention relates to a method for assessing whether a patient suffers from cancer, such as hepatocellular carcinoma, or is prone to suffering from cancer, such as hepatocellular carcinoma, wherein said method comprises determining the amount of soluble AXL in a sample from the patient. The patient is assessed to suffer from cancer or to be prone to suffering from cancer when the amount of soluble AXL is increased in comparison to a control. The present invention relates to the use of soluble AXL for assessing whether a patient suffers from cancer, such as hepatocellular carcinoma, or is prone to suffering from cancer, such as hepatocellular carcinoma. Also a kit for use in the methods of the present invention is provided.

Abstract: The present invention relates to novel monomaleimide-functionalized platinum compounds of formula (I), including in particular novel monomaleimide-functionalized oxaliplatin and carboplatin derivatives, as well as their use as medicaments, particularly for the treatment or prevention of cancer.

Abstract: The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans and animals including mammals and birds. More particularly, it relates to subunit vaccines that are effective against pathogens causing infections thereof for use in humans and animals including mammals and birds. The present invention specifically provides a novel vaccine formulation suitable for ocular immunization comprising a subunit vaccine antigen in an amount to provoke a protective immune response and at least two adjuvants of which one is corpuscular. It further provides a method for inducing a local and systemic immune response and methods for preventing recurrence of ocular infections and/or modulates the occurrence and/or severity of sequels.

Abstract: The disclosed subject matter relates to a method for determining phase offsets in a complex-valued image in Magnetic Resonance Imaging, including the steps of, immobilising an object and acquiring a first image thereof at a predetermined first echo time and a second image thereof at a predetermined second echo time, the first and second images being separated into first and second magnitude images and first and second phase images, respectively, wherein a ratio between said first echo time and said second echo time is chosen to be n:(n+1), n being a positive integer; generating, pixel by pixel, a phase evolution image; and subtracting, pixel by pixel, an n-fold of the phase evolution image from the first phase image to obtain a phase offset image containing said phase offsets.

Abstract: Disclosed is a method for the detection of an IgM antibody specific for a flavivirus in a sample, comprising the steps of (a) contacting the sample with a solid support comprising immobilised IgM-binding molecules, (b) allowing binding of IgM antibodies in the sample to the IgM binding molecules on the solid support so that the IgM antibodies are also immobilised on the solid support, and (c) detecting IgM antibodies specific for a flavivirus by allowing binding of a complex comprising (i) an antiparallel dimer of soluble flavivirus Protein E (sE) and (ii) a marker and identifying the binding of the complex to the specific flavivirus IgM antibody by detecting the marker; and a kit suitable for performing the method.

Abstract: The present invention relates to a human mast cell line corresponding to deposit number CNCM I-4551 and also to the lines derived therefrom, in particular the derived lines corresponding respectively to deposit numbers CNCM I-4552 and CNCM I-4553, and to the uses thereof, in particular for screening for compounds of therapeutic interest.